{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:02:04Z","timestamp":1767146524517,"version":"build-2238731810"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jve.2023.100331","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T21:53:55Z","timestamp":1686952435000},"page":"100331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["HIV remission trial investigators\u2019 attitudes towards risk and risk mitigation in trials that include treatment interruption"],"prefix":"10.1016","volume":"9","author":[{"given":"Eunice Akinyi","family":"Okumu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail E.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Golin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriste","family":"Kuczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuchanart Q.","family":"Ormsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly L.","family":"Peay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jve.2023.100331_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12910-021-00651-1","article-title":"Ethics of HIV cure research: an unfinished agenda","volume":"22","author":"Dub\u00e9","year":"2021","journal-title":"BMC Med Ethics"},{"issue":"8","key":"10.1016\/j.jve.2023.100331_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri3262","article-title":"Towards an HIV cure: a global scientific strategy","volume":"12","author":"Deeks","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jve.2023.100331_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/25787489.2022.2054613","article-title":"\u201cWe are looking at the future right now\u201d: community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States","volume":"23","author":"Dub\u00e9","year":"2022","journal-title":"HIV Res Clin Pract"},{"issue":"4","key":"10.1016\/j.jve.2023.100331_bib4","first-page":"270","article-title":"Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk\/benefit assessment","volume":"44","author":"Henderson","year":"2018","journal-title":"J Med Ethics"},{"issue":"3","key":"10.1016\/j.jve.2023.100331_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25260","article-title":"Going off antiretroviral treatment in a closely monitored HIV \u201ccure\u201d trial: longitudinal assessments of acutely diagnosed trial participants and decliners","volume":"22","author":"Henderson","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"10.1016\/j.jve.2023.100331_bib6","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","article-title":"Recommendations for analytical antiretroviral treatment interruptions in HIV research trials\u2014report of a consensus meeting","volume":"6","author":"Julg","year":"2019","journal-title":"The Lancet HIV"},{"issue":"220 Suppl 1","key":"10.1016\/j.jve.2023.100331_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jiz173","article-title":"Risk to nonparticipants in HIV remission studies with treatment interruption: a symposium","volume":"220","author":"Eyal","year":"2019","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.jve.2023.100331_bib8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bioe.12830","article-title":"Symposium on risks to bystanders in clinical research: an introduction","volume":"34","author":"Eyal","year":"2020","journal-title":"Bioethics"},{"issue":"1","key":"10.1016\/j.jve.2023.100331_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2055-6640(20)30009-1","article-title":"A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption","volume":"6","author":"Peluso","year":"2020","journal-title":"J Virus Erad [Internet"},{"issue":"5","key":"10.1016\/j.jve.2023.100331_bib10","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1007\/s10461-021-03504-5","article-title":"Attitudes about analytic treatment interruption (ATI) in HIV remission trials with different antiretroviral therapy (ART) resumption criteria","volume":"26","author":"Peay","year":"2022","journal-title":"AIDS Behav"},{"issue":"1","key":"10.1016\/j.jve.2023.100331_bib11","article-title":"Motivations, barriers and experiences of participants in an HIV reservoir trial","volume":"7","author":"De Scheerder","year":"2021","journal-title":"J Virus Erad [Internet"},{"issue":"4","key":"10.1016\/j.jve.2023.100331_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2055-6640(20)30028-5","article-title":"From early AIDS vaccine to HIV cure research with analytical treatment interruption trials: a study participant testimonial","volume":"5","author":"Freshwater","year":"2019","journal-title":"J Virus Erad"},{"issue":"1","key":"10.1016\/j.jve.2023.100331_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12981-020-00321-z","article-title":"Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies","volume":"17","author":"Lau","year":"2020","journal-title":"AIDS Res Ther"},{"issue":"2","key":"10.1016\/j.jve.2023.100331_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Adm Policy Ment Health"},{"key":"10.1016\/j.jve.2023.100331_bib17","series-title":"The Lancet HIV","article-title":"Recommendations for analytical antiretroviral treatment interruptions in HIV research trials\u2014report of a consensus meeting","author":"Julg","year":"2019"},{"issue":"3","key":"10.1016\/j.jve.2023.100331_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAI.0000000000002256","article-title":"HIV status disclosure and sexual transmission risks among people who are living with HIV and receiving treatment for non-HIV sexually transmitted infections, cape town, South Africa","volume":"83","author":"Kalichman","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.jve.2023.100331_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211921","article-title":"Factors associated with HIV status disclosure to partners and its outcomes among HIV-positive women attending Care and Treatment Clinics at Kilimanjaro region, Tanzania","volume":"14","author":"Damian","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jve.2023.100331_bib20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2105\/AJPH.2010.300102","article-title":"Facilitating HIV disclosure across diverse settings: a review","volume":"101","author":"Obermeyer","year":"2011","journal-title":"Am J Publ Health"},{"issue":"1","key":"10.1016\/j.jve.2023.100331_bib21","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1186\/s12889-019-8097-y","article-title":"Sero-positive HIV result disclosure to sexual partner in Ethiopia: a systematic review and meta-analysis","volume":"19","author":"Mekonnen","year":"2019","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.jve.2023.100331_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/eahr.500172","article-title":"The essential need for trust when transmission risk cannot be eliminated in HIV remission trials (in press)","author":"Rennie","year":"2023","journal-title":"Ethics Hum Res"}],"updated-by":[{"DOI":"10.1016\/j.jve.2023.100340","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000}}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664023000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664023000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T09:24:46Z","timestamp":1729589086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664023000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2055664023000171"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2023.100331","relation":{},"ISSN":["2055-6640"],"issn-type":[{"value":"2055-6640","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV remission trial investigators\u2019 attitudes towards risk and risk mitigation in trials that include treatment interruption","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2023.100331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100331"}}